PicoCELA Inc. (NASDAQ:PCLA) Sees Significant Growth in Short Interest

PicoCELA Inc. (NASDAQ:PCLA) was the recipient of a large increase in short interest in July. As of July 31st, there was short interest totaling 429,834 shares, an increase of 113.0% from the July 15th total of 201,780 shares. Based on an average trading volume of 146,360 shares, the short-interest ratio is presently 2.9 days. Approximately 1,074.6% of the shares of the stock are short sold.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in PicoCELA stock. XTX Topco Ltd purchased a new position in shares of PicoCELA Inc. (NASDAQ:PCLA) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 44,648 shares of the company’s stock, valued at approximately $72,000. XTX Topco Ltd owned approximately 0.16% of PicoCELA as of its most recent filing with the Securities and Exchange Commission (SEC).

PicoCELA Stock Up 6.6%

PCLA traded up $0.42 during trading on Friday, reaching $6.76. The stock had a trading volume of 265,414 shares, compared to its average volume of 357,809. PicoCELA has a one year low of $1.35 and a one year high of $19.61. The business has a 50-day moving average of $5.41 and a 200-day moving average of $4.32.

Analyst Upgrades and Downgrades

PCLA has been the subject of several recent analyst reports. Wall Street Zen raised PicoCELA to a “hold” rating in a report on Saturday, July 25th. Weiss Ratings downgraded shares of PicoCELA from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, August 3rd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, PicoCELA has an average rating of “Sell”.

About PicoCELA

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.